For Biogen's Aduhelm, narrow coverage from CMS 'could effectively spell the end': analyst

For Biogen's Aduhelm, narrow coverage from CMS 'could effectively spell the end': analyst

Source: 
Fierce Pharma
snippet: 

The CMS proposal “could effectively spell the end for Aduhelm,” RBC Capital Markets analyst Brian Abrahams wrote in a Tuesday note to clients. That’s because older people covered by Medicare make up the bulk of the Alzheimer’s patient population, and restrictive access there would be a serious blow to Aduhelm’s market potential.